美国 · SEC FORM 4
C4 Therapeutics, Inc.
CCCC · Nasdaq · CIK 0001662579 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
9 同一窗口内观察到的 Form 4 交易行
0 sales · 9 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-02-08 · Koppikar Utpal.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 40,395,665
- 上期报告
- 40,189,287
- 日均成交量
- 2,289,003
- 回补天数
- 17.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-02-08 | Koppikar Utpal | 买入 (P) | Common Stock | 5,667 | USD 5.60 | USD 31,735 | SEC 申报 ↗ |
| 2022-04-12 | Hirsch Andrew | 买入 (P) | Common Stock | 10,000 | USD 8.40 | USD 84,000 | SEC 申报 ↗ |
| 2020-10-06 | Salter Malcolm | 买入 (P) | Common Stock | 1,315 | USD 19.00 | USD 24,985 | SEC 申报 ↗ |
| 2020-10-06 | MCKEE WILLIAM | 买入 (P) | Common Stock | 5,263 | USD 19.00 | USD 99,997 | SEC 申报 ↗ |
| 2020-10-06 | COHEN MARC A | 买入 (P) | Common Stock | 5,030 | USD 19.00 | USD 95,570 | SEC 申报 ↗ |
Form 4 申报证据
45 transaction lines in the latest 365-day window; 321 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | GROGAN DONNA ROY | 奖励／授予 (A) | Common Stock | 4,618 | USD 3.14 | USD 14,501 | SEC 申报 ↗ |
| 2026-10-01 | Anderson Kenneth Carl | 奖励／授予 (A) | Common Stock | 3,662 | USD 3.14 | USD 11,499 | SEC 申报 ↗ |
| 2026-09-18 | Adams Kendra | 期权行权／转换 (M) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | GROGAN DONNA ROY | 奖励／授予 (A) | Common Stock | 4,618 | USD 3.14 | USD 14,501 | SEC 申报 ↗ |
| 2026-10-01 | Anderson Kenneth Carl | 奖励／授予 (A) | Common Stock | 3,662 | USD 3.14 | USD 11,499 | SEC 申报 ↗ |
| 2026-09-18 | Adams Kendra | 期权行权／转换 (M) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-18 | Adams Kendra | 代扣税 (F) | Common Stock | 2,775 | USD 3.39 | USD 9,407 | SEC 申报 ↗ |
| 2026-07-10 | REYNO LEONARD | 期权行权／转换 (M) | Common Stock | 15,325 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-10 | REYNO LEONARD | 代扣税 (F) | Common Stock | 7,397 | USD 4.06 | USD 30,032 | SEC 申报 ↗ |
| 2026-07-01 | GROGAN DONNA ROY | 奖励／授予 (A) | Common Stock | 3,341 | USD 4.34 | USD 14,500 | SEC 申报 ↗ |
| 2026-07-01 | Anderson Kenneth Carl | 奖励／授予 (A) | Common Stock | 2,650 | USD 4.34 | USD 11,501 | SEC 申报 ↗ |
| 2026-06-01 | Anderson Kenneth Carl | 期权行权／转换 (M) | Common Stock | 1,070 | USD 2.11 | USD 2,258 | SEC 申报 ↗ |
| 2026-04-01 | GROGAN DONNA ROY | 奖励／授予 (A) | Common Stock | 5,370 | USD 2.70 | USD 14,499 | SEC 申报 ↗ |
| 2026-04-01 | Anderson Kenneth Carl | 奖励／授予 (A) | Common Stock | 4,259 | USD 2.70 | USD 11,499 | SEC 申报 ↗ |
| 2026-02-15 | Hirsch Andrew | 期权行权／转换 (M) | Common Stock | 20,400 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-15 | Hirsch Andrew | 代扣税 (F) | Common Stock | 9,057 | USD 1.89 | USD 17,118 | SEC 申报 ↗ |
| 2026-02-14 | Schick Kelly | 期权行权／转换 (M) | Common Stock | 20,950 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Schick Kelly | 代扣税 (F) | Common Stock | 7,269 | USD 1.89 | USD 13,738 | SEC 申报 ↗ |
| 2026-02-14 | REYNO LEONARD | 期权行权／转换 (M) | Common Stock | 30,950 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | REYNO LEONARD | 代扣税 (F) | Common Stock | 16,579 | USD 1.89 | USD 31,334 | SEC 申报 ↗ |
| 2026-02-14 | Mossler Mark | 期权行权／转换 (M) | Common Stock | 9,420 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Mossler Mark | 代扣税 (F) | Common Stock | 3,268 | USD 1.89 | USD 6,177 | SEC 申报 ↗ |
| 2026-02-14 | Mahaney Paige | 期权行权／转换 (M) | Common Stock | 7,050 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Mahaney Paige | 代扣税 (F) | Common Stock | 2,446 | USD 1.89 | USD 4,623 | SEC 申报 ↗ |
| 2026-02-14 | Hirsch Andrew | 期权行权／转换 (M) | Common Stock | 81,725 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Hirsch Andrew | 代扣税 (F) | Common Stock | 39,154 | USD 1.89 | USD 74,001 | SEC 申报 ↗ |
| 2026-02-14 | Boyle Scott N | 期权行权／转换 (M) | Common Stock | 20,950 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Boyle Scott N | 代扣税 (F) | Common Stock | 7,269 | USD 1.89 | USD 13,738 | SEC 申报 ↗ |
| 2026-02-14 | Adams Kendra | 期权行权／转换 (M) | Common Stock | 30,950 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-14 | Adams Kendra | 代扣税 (F) | Common Stock | 15,381 | USD 1.89 | USD 29,070 | SEC 申报 ↗ |
| 2026-02-13 | Schick Kelly | 期权行权／转换 (M) | Common Stock | 5,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-13 | Schick Kelly | 代扣税 (F) | Common Stock | 1,735 | USD 1.89 | USD 3,279 | SEC 申报 ↗ |
| 2026-02-13 | Schick Kelly | 奖励／授予 (A) | Common Stock | 200,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CCCC |
| CIK | 0001662579 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 321 transaction lines from 2020-10-06 to 2026-10-01 5 P purchase lines · 52 S sale lines · 264 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.